Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.
Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.
Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.
Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.
Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.
In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.
Cybin Inc. (AMEX:CYBN) has initiated a feasibility study utilizing Kernel's Flow technology to objectively measure the effects of ketamine on brain activity during psychedelic experiences. This study is poised to gather quantitative data, a significant advancement compared to previous subjective reporting methods. Authorized by the FDA in October 2021, the study will involve participants receiving either low-dose ketamine or a placebo. Cybin retains exclusive rights to innovations resulting from the study, reinforcing its commitment to advancing psychedelic therapies.
Cybin Inc. has completed in vivo preclinical studies of its deuterated psilocybin analog CYB003 for treating major depressive disorder (MDD). The studies indicate CYB003 is well-tolerated and shows promising pharmacological properties, including a 50% reduction in dosage variability and faster onset compared to classic psilocybin. The Company plans to submit an IND to the FDA in Q2 2022 and initiate Phase 1/2a trials by mid-2022, aiming to advance CYB003 as a potential treatment for MDD and alcohol use disorder.
Cybin Inc. announced milestones achieved by its subsidiary, Adelia Therapeutics, in accordance with a Transaction Agreement dated December 4, 2020. As a result, 90,546 Class B common shares will be issued to Adelia shareholders, fulfilling an obligation of approximately
Cybin Inc. (AMEX:CYBN) has announced the recruitment for a feasibility study evaluating the effects of ketamine on participants using Kernel Flow's neuroimaging technology. Participants will experience either a low dose of ketamine or a placebo, while their brain activity is monitored. This groundbreaking research aims to quantify psychedelic experiences, potentially paving the way for larger studies that bridge psychedelics and therapeutics. CEO Doug Drysdale emphasized the study's significance in enhancing understanding of psychedelic effects on mental health.
Cybin, a biopharmaceutical company focused on mental health therapeutics, announced that CEO Doug Drysdale will present at the 2022 Virtual Growth Conference from March 28 to 30, 2022. The presentation will be available on demand starting March 28 at 9:00 a.m. ET. Interested attendees can register to access the conference and listen to the presentation via the company's website. Founded in 2019 and headquartered in Canada, Cybin is dedicated to advancing psychedelics for therapeutic use through innovative drug discovery and delivery systems.
Cybin Inc. (AMEX:CYBN) announced participation by CEO Doug Drysdale in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 8:40 a.m. ET. The event will highlight the company’s focus on transforming psychedelics into therapeutics for mental health issues. A webcast will be available for those interested in listening to the discussion. Cybin, operational in Canada, the US, UK, and Ireland, is committed to the development of innovative therapeutic solutions leveraging proprietary drug discovery platforms.
Cybin announced that its subsidiary, Adelia Therapeutics, has reached a milestone under a December 4, 2020, agreement, resulting in the issuance of 17,239.5 Class B shares. This issuance satisfies approximately CAD $233,424 due to Adelia's shareholders, priced at CAD $13.54 per share. The shares are exchangeable for Cybin shares on a 10:1 basis, with specific timelines for exchange eligibility extending to 2023. Cybin focuses on advancing psychedelics for therapeutic uses, aiming to address mental health issues.
Cybin, a biopharmaceutical company focused on advancing "Psychedelics to Therapeutics™", will have its CEO Doug Drysdale participate in a fireside chat at the Aegis Virtual Conference on February 24, 2022, at 2:00 p.m. ET. The conference runs from February 23 to February 25, 2022. Interested viewers can access the event through a provided link, with an archived webcast available later on Cybin's investor relations site. Founded in 2019 and headquartered in Canada, Cybin aims to create safe therapeutics for mental health issues.
Cybin announced significant advancements in its clinical programs during Q3 2021, focusing on psychedelic therapies for mental health. The company is preparing for a Phase 1/2a trial of CYB003 targeting major depressive disorder and alcohol use disorder, following a supportive meeting with the UK MHRA. Financially, it reported C$63.6 million in cash, with a Q3 net loss of C$17.2 million. Cybin continues to build its intellectual property portfolio, including a recent U.S. patent for CYB004.
Cybin Inc. has received a crucial composition of matter patent for its investigational deuterated DMT compound, CYB004, from the U.S. Patent and Trademark Office. This patent, expiring in 2041, reinforces the company’s intellectual property in psychedelics and protects CYB004 as a new chemical entity. Preclinical studies show that CYB004 could alleviate negative experiences linked to classical DMT while boosting therapeutic effects. The company plans to submit a clinical trial application for a pilot study of CYB004 in mid-2022, with hopes for significant advancements in treating anxiety disorders.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
What is Cybin Inc.?
What does Cybin Inc. specialize in?
What are the core areas of Cybin's research?
What recent achievements has Cybin Inc. made?
Can you name some of Cybin's product candidates?
How does Cybin contribute to mental health treatment?
Has Cybin formed any strategic partnerships?
What is the significance of Cybin's drug delivery technologies?
What conditions are Cybin's therapies aimed at treating?
Where can I find the latest news about Cybin Inc.?
